Compare
Kymera Therapeutics, Inc. vs X4 Pharmaceuticals, Inc vs Scilex Holding Co vs Protalix BioTherapeutics, Inc.
| Latest fiscal year | Kymera Therapeutics, Inc. KYMR | X4 Pharmaceuticals, Inc XFOR | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Protalix BioTherapeutics, Inc. PLX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $39.21M | $35.11M | $30.25M | $52.74M |
| Revenue growth (YoY) | -16.7% | n/m | -46.5% | -1.2% |
| Gross margin | 0.0% (computed) | 83.6% (computed) | 65.0% (computed) | 48.8% (computed) |
| Operating margin | -891.1% | -247.4% | n/m | -10.4% |
| Net margin | -794.0% | -225.6% | n/m | -12.5% |
| Net income | -$311.35M | -$79.20M | -$374.05M | -$6.60M |
| EPS (Diluted) | -$3.69 | -$1.87 | -$36.48 | -$0.08 |
| Operating cash flow | -$232.89M | -$85.62M | $3.82M | -$11.99M |
| Free cash flow | -$234.34M | -$85.62M | $3.68M | -$13.63M |
| Cash & equivalents | $357.01M | $217.05M | $4.96M | $14.68M |
| Total assets | $1.74B | $290.46M | $364.98M | $82.35M |
| Total liabilities | $163.15M | $104.17M | $576.73M | $34.12M |
| Shareholders' equity | $1.58B | $186.29M | -$207.78M | $48.23M |
| Return on year-end equity | -19.7% | -42.5% | n/a | -13.7% |
| Shares outstanding | 81.32M | 90.91M | 7.03M | 80.43M |
Revenue, most recent five fiscal years
| Fiscal year | Kymera Therapeutics, Inc. | X4 Pharmaceuticals, Inc | Scilex Holding Co | Protalix BioTherapeutics, Inc. |
|---|---|---|---|---|
| Latest | $39.21M Ended 2025-12-31 | $35.11M Ended 2025-12-31 | n/a | $52.74M Ended 2025-12-31 |
| 1 year earlier | $47.07M Ended 2024-12-31 | $2.56M Ended 2024-12-31 | n/a | $53.40M Ended 2024-12-31 |
| 2 years earlier | $78.59M Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a | $65.49M Ended 2023-12-31 |
| 3 years earlier | $46.83M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a | $47.64M Ended 2022-12-31 |
| 4 years earlier | $72.83M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a | $38.35M Ended 2021-12-31 |